Literature DB >> 29929463

Treatment of 'Diabesity': Beyond Pharmacotherapy.

Himadri Singh1, Vijayalakshmi Venkatesan1.   

Abstract

Obesity is a prominent risk factor for type 2 diabetes. Management of type 2 diabetes requires weight management in addition to glycemic parameters. For obese type 2 diabetes patients, metformin, Sodium-glucose co-transporter-2 inhibitors or Glucagon-Like Peptide-1 Receptor Agonists should be prescribed as the first priority for controlling both hyperglycemia and body weight or fat distribution. The combination of these drugs with sulfonylureas, thiazolidinediones, and insulin may also be required in chronic cases. These drugs cause weight gain. Fortunately, many phytochemicals having a beneficial effect on diabetes and obesity, have minimum side-effects as compared to synthetic drugs. This review discusses the treatment strategies for controlling glycemia and weight management, with the focus on anti-diabetic drugs and phytochemicals. Glucagonostatic role, activation of Adenosine monophosphate-activated protein kinase and adipocyte targeting potential of anti-diabetic drugs and phytochemicals are also discussed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Obesity; bioactivity; curcumin; diabesity; diabetes; flavonoids; pharmacotherapy.

Mesh:

Substances:

Year:  2018        PMID: 29929463     DOI: 10.2174/1389450119666180621093833

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  1 in total

1.  Identification of new enterosynes using prebiotics: roles of bioactive lipids and mu-opioid receptor signalling in humans and mice.

Authors:  Anne Abot; Eve Wemelle; Patrice D Cani; Claude Knauf; Claire Laurens; Adrien Paquot; Nicolas Pomie; Deborah Carper; Arnaud Bessac; Xavier Mas Orea; Christophe Fremez; Maxime Fontanie; Alexandre Lucas; Jean Lesage; Amandine Everard; Etienne Meunier; Gilles Dietrich; Giulio G Muccioli; Cedric Moro
Journal:  Gut       Date:  2020-10-05       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.